Pro-BNP Risk Score Calculator

Clinical calculation support · Verify results before clinical use

NT-proBNP Clinical Interpretation

Enter the patient’s age and NT-proBNP concentration, then select the clinical setting.

Evidence-based thresholds

For adults aged 18–120 years.

Use the reported NT-proBNP value; do not substitute BNP.

Interpretation thresholds differ between acute and non-acute settings.

Interpretation
Enter patient data

How to interpret NT-proBNP

NT-proBNP is a biomarker used with symptoms, examination, ECG, imaging, and other investigations when heart failure is suspected. It is associated with prognosis in established heart failure, but a concentration alone does not provide an individualized mortality estimate.

Thresholds used by this tool

SettingThresholdMeaning
Non-acute<125 pg/mLHeart failure is less likely; interpret with the clinical assessment.
Non-acute, age-adjusted≥125 / ≥250 / ≥500 pg/mLHF is more likely at age <50 / 50–75 / >75 years, respectively; further assessment may be warranted.
Acute<300 pg/mLAcute heart failure is unlikely, though clinical exceptions occur.
Acute, age-specific rule-in≥450 / ≥900 / ≥1800 pg/mLSupports acute HF at age <50 / 50–75 / >75 years, respectively; not diagnostic by itself.

Important factors affecting results

  • Older age, atrial fibrillation, and renal dysfunction can increase NT-proBNP.
  • Obesity may result in lower concentrations than expected.
  • Other cardiac and non-cardiac conditions can elevate NT-proBNP.
  • Use the correct assay and units; BNP and NT-proBNP cutoffs are not interchangeable.

References

McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
2026 ESC Guidelines for the management of heart failure. European Society of Cardiology / European Heart Journal. 2026. Age-adjusted outpatient NT-proBNP thresholds discussed in the guideline. Official guideline
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895–e1032. doi:10.1161/CIR.0000000000001063
Clinical disclaimer: This tool provides a threshold-based aid for interpreting NT-proBNP in suspected heart failure. It is not a validated mortality risk score, does not diagnose or exclude heart failure on its own, and must not replace clinical judgement or urgent assessment when indicated. Interpret results in the context of symptoms, examination, renal function, rhythm, body habitus, and other investigations.